Valuation: Vaxcyte, Inc.

Capitalization 699.46Cr 600.98Cr 549.87Cr 522.2Cr 961.53Cr 67TCr 977.92Cr 6.58TCr 2.55TCr 32TCr 2.63TCr 2.57TCr 1,11100Cr P/E ratio 2026 *
-5.69x
P/E ratio 2027 * -7.07x
Enterprise value 693.44Cr 595.81Cr 545.14Cr 517.71Cr 953.26Cr 67TCr 969.5Cr 6.52TCr 2.53TCr 32TCr 2.6TCr 2.55TCr 1,10200Cr EV / Sales 2026 *
-
EV / Sales 2027 * 75.4x
Free-Float
99.47%
Yield 2026 *
-
Yield 2027 * -
1 day-7.54%
1 week-10.28%
Current month-15.37%
1 month-22.31%
3 months-13.76%
6 months-2.20%
Current year+4.98%
1 week 48.24
Extreme 48.24
54.74
1 month 48.24
Extreme 48.24
63.11
Current year 43.94
Extreme 43.945
65
1 year 29.08
Extreme 29.08
65
3 years 27.66
Extreme 27.66
121.06
5 years 16.78
Extreme 16.78
121.06
10 years 15.51
Extreme 15.51
121.06
Manager TitleAgeSince
Corporate Officer/Principal 62 27/05/2013
Chief Executive Officer 58 01/11/2013
Director of Finance/CFO 56 01/05/2020
Director TitleAgeSince
Director/Board Member 58 01/11/2013
Director/Board Member 59 16/09/2021
Director/Board Member 58 01/05/2018
Change 5d. change 1-year change 3-years change Capi.($)
-7.54%-10.28%+52.09%-0.39% 699.46Cr
-2.54%-2.26%+33.94%+75.07% 4.89TCr
-1.05%-6.14%+66.31%+52.72% 4.53TCr
-1.82%+3.14%+57.30%+469.34% 2.32TCr
-0.78%-4.81%-4.23%-15.34% 2.25TCr
+0.06%-2.20%+38.78%-21.80% 1.74TCr
+0.39%+1.90%+27.97%-40.10% 1.62TCr
0.00%-12.54%+36.09%+202.39% 1.34TCr
-5.04%-14.15%-32.89%+888.89% 1.24TCr
+1.84%-6.34%+30.39% - 1.26TCr
Average -1.67%-5.32%+30.58%+178.98% 2.19TCr
Weighted average by Cap. -1.46%-4.37%+35.85%+142.28%

Financials

2026 *2027 *
Net sales - 8.71Cr 7.49Cr 6.85Cr 6.51Cr 12Cr 839.52Cr 12Cr 82Cr 32Cr 397.21Cr 33Cr 32Cr 1.38TCr
Net income -122.73Cr -105.45Cr -96Cr -92Cr -168.71Cr -12TCr -171.59Cr -1.15TCr -447.56Cr -5.59TCr -460.61Cr -450.85Cr -19TCr -104.74Cr -90Cr -82Cr -78Cr -143.99Cr -10TCr -146.44Cr -985.54Cr -381.96Cr -4.77TCr -393.1Cr -384.77Cr -17TCr
Net Debt -6.02Cr -5.17Cr -4.73Cr -4.49Cr -8.27Cr -579.86Cr -8.42Cr -57Cr -22Cr -274.35Cr -23Cr -22Cr -956.28Cr -42Cr -36Cr -33Cr -32Cr -58Cr -4.08TCr -59Cr -398.74Cr -154.54Cr -1.93TCr -159.04Cr -155.67Cr -6.73TCr
Logo Vaxcyte, Inc.
Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.
Employees
507
Date Price Change Volume
18/26/18 48.44 $ -7.54% 17,15,055
15/26/15 52.39 $ -2.13% 12,94,465
14/26/14 53.53 $ -1.33% 13,63,672
13/26/13 54.25 $ +0.41% 14,23,838
12/26/12 54.03 $ +0.07% 12,60,710
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
48.44USD
Average target price
109.00USD
Spread / Average Target
+125.02%

Quarterly revenue - Rate of surprise